Physician profile
Santa M Merle
NPI 1831300805
$84,038.23
in general payments reported to CMS, 2019-2025
52 companies · $6,958 in 2025
The $6,958 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,467 · 2020: $14K · 2021: $13K · 2022: $23K · 2023: $15K · 2024: $7,188 · 2025: $6,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,625 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,639.20 |
| Food and Beverage | $12,897.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,625.00 |
| Education | $299.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34,179.84 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Abbvie INC. | $14,561.26 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $12,230.69 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Janssen Pharmaceuticals, INC | $4,425.66 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals Lp | $2,873.27 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Genzyme Corporation | $2,649.44 | 2020-2025 | |
| Pbg Puerto Rico LLC | $2,098.42 | 2019-2025 | |
| Amgen INC. | $1,615.07 | 2019-2025 | Xgeva, Kyprolis, Lumakras |
| Genentech USA, INC. | $1,563.66 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,103.28 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Janssen Scientific Affairs, LLC | $975.00 | 2023 | Imbruvica |
| Sobi, INC | $612.26 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $476.81 | 2022-2025 | |
| Janssen Biotech, INC. | $378.93 | 2019-2021 | |
| Puma Biotechnology, INC. | $350.27 | 2021-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $328.45 | 2020-2025 | Monjuvi, Jakafi, Zynyz |
| Regeneron Healthcare Solutions, INC. | $325.98 | 2024-2025 | Libtayo |
| Bayer Puerto Rico INC. | $302.55 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
| Pfizer INC. | $246.29 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $243.01 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Eisai INC. | $207.53 | 2021-2024 | |
| Gilead Sciences, INC. | $191.84 | 2022-2025 | Trodelvy |
| Tempus Ai, INC | $190.08 | 2024-2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $157.57 | 2021-2025 | Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $149.68 | 2021 | |
| Exelixis INC. | $147.49 | 2023-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $125.00 | 2022 | |
| Seagen INC. | $122.47 | 2019-2023 | Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $117.61 | 2022 | |
| Pfizer Pharmaceuticals LLC | $112.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Horizon Therapeutics Plc | $93.75 | 2019 | |
| Astellas Pharma US INC | $86.34 | 2021-2023 | Xospata |
| Beigene USA, INC. | $60.88 | 2020-2025 | Brukinsa |
| Taiho Oncology, INC. | $57.12 | 2019-2021 | |
| Glaxosmithkline, LLC. | $51.20 | 2020-2024 | Zejula, Jemperli, Ojjaara |
| Pharmaand Gmbh | $49.96 | 2025 | Rubraca |
| Tolmar, INC. | $49.96 | 2025 | Rubraca, Eligard |
| Clovis Oncology, INC. | $46.96 | 2022 | |
| Jazz Pharmaceuticals INC. | $46.72 | 2021-2022 | |
| Caris Mpi, INC. | $46.29 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $45.53 | 2023-2024 | Bavencio |
| Lilly USA, LLC | $40.92 | 2020 | |
| Beone Medicines USA, INC. | $40.20 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $33.17 | 2025 | |
| Adaptive Biotechnologies Corporation | $23.54 | 2022 | |
| Array Biopharma INC | $21.67 | 2025 | Braftovi, Mektovi, Lorbrena |
| Genmab U.S., INC. | $21.16 | 2023 | Epkinly |
| Shire North American Group INC | $19.37 | 2019 | |
| Partner Therapeutics, INC. | $17.43 | 2020 | |
| Celgene Corporation | $12.91 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santa Merle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.